Document is current
Any future updates will be listed below
-
Authors
Nim, Satra http://orcid.org/0000-0002-7791-1238
O’Hara, Darren M. http://orcid.org/0000-0002-0766-2061
Corbi-Verge, Carles http://orcid.org/0000-0002-7654-4405
Perez-Riba, Albert
Fujisawa, Kazuko
Kapadia, Minesh
Chau, Hien
Albanese, Federica
Pawar, Grishma
De Snoo, Mitchell L. http://orcid.org/0000-0002-2057-7419
Ngana, Sophie G.
Kim, Jisun http://orcid.org/0000-0002-4863-9773
El-Agnaf, Omar M. A.
Rennella, Enrico
Kay, Lewis E.
Kalia, Suneil K. http://orcid.org/0000-0003-2054-1915
Kalia, Lorraine V. http://orcid.org/0000-0002-9384-1305
Kim, Philip M. http://orcid.org/0000-0003-3683-152X
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-159531, MC2-157081, PJT-153279)
Michael J. Fox Foundation for Parkinson’s Research (MJFF-001076, MJFF-001076)
Parkinson’s UK (K-1405)
Michael J. Fox Foundation for Parkinson’s Research
- License Information
-
More Information
Article History
Received: 21 May 2021
Accepted: 14 March 2023
First Online: 19 April 2023
Competing interests
: University of Toronto has submitted a patent application covering composition and use of the peptides, as well as the screening methods (US Patent 63/289,912, currently pending with PCT filed) with S.N., C.C.V., S.K.K., L.V.K., and P.M.K. as inventors. S.K.K., L.V.K., and P.M.K. have co-founded Synepark Therapeutics Inc to commercialize aspects of this research. The remaining authors declare no competing interests.
